VentriPoint Diagnostics Ltd. (V:VPT)
Business Focus: Advanced Medical Equipment & Technology (NEC)
May 14, 2024 02:30 pm ET
Ventripoint Applies for Extension of Non-Brokered Convertible Debenture Private Placement
Toronto, Ontario – TheNewswire - May 14, 2024 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Corporation”),
(TSXV:VPT) announces that it will seek approval of TSX Venture Exchange
(“TSXV” or the “Exchange”) to extend its previously
announced non-brokered private placement (“Offering”) of
unsecured convertible debentures (“Debentures”). (See
press releases dated April 11, 2024 and May 13, 2024).
May 13, 2024 06:10 am ET
Ventripoint Announces Closing of First Tranche of Non-Brokered Convertible Debenture Private Placement
Toronto, Ontario – TheNewswire - May 13, 2024 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Corporation”),
(TSXV:VPT) announces that it has closed the insider led first tranche of
its previously announced non-brokered private placement of unsecured
convertible debentures (“Debentures”) for gross proceeds of
$941,000.
May 06, 2024 06:10 am ET
Ventripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to U.S Food and Drug Administration
Toronto, Ontario – TheNewswire - May 6, 2024 -
Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT); (OTC:VPTDF)
has reached another development milestone by
submitting its next generation of software, VMS+4.0, to the U.S. Food
and Drug Administration (“FDA”).
May 01, 2024 06:05 am ET
Duke University Health Center -- One of America's Top Heart-care Institutions and Innovators -- Purchases Ventripoint's AI Heart-scan Technology
Toronto, Ontario – TheNewswire - May 1, 2024 -
Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT); (OTC:VPTDF)
is pleased to announce that Duke University
Health Center has purchased its second VMS+ unit from Ventripoint ,
which processes ultrasound images of the heart to generate MRI-quality
measurements in minutes.
Apr 11, 2024 06:05 am ET
Ventripoint Announces Non-Brokered Convertible Debenture Private Placement
Toronto, Ontario – TheNewswire - April 11, 2024 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Corporation”),
(TSXV:VPT) announces that it intends to complete, subject to TSXV
Venture Exchange (the “Exchange”) acceptance, a non-brokered
private placement of up to CDN$3,000,000 (the “Offering”) of
unsecured convertible debentures (“Debentures”).
Depending on market conditions, the Corporation may increase the size
of the Offering, subject to approval of the Exchange.
Mar 28, 2024 06:15 am ET
Ventripoint Diagnostics Provides Corporate Update and Announces Conference Call
Toronto, Ontario – TheNewswire –
March 28, 2024 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to provide a corporate update on the
Company’s current status and the outlook for 2024.
Mar 04, 2024 06:20 am ET
Enhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to Use
***Faster, User Friendly Cardio AI Imaging Product for
Commercial Roll Out***
Feb 20, 2024 09:15 am ET
Ventripoint Successfully Showcases A.I.-Powered Heart-Scanning Technology at Prestigious International Cardiology Conferences
Hamburg, Germany — TheNewswire --- February 20, 2024 — Ventripoint
Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) is
delighted to report its participation at the 53rd annual meeting of
the German Society for Thoracic, Heart and Vascular Surgery. The
event, held Feb. 19, was held in conjunction with the annual meeting
of the German Society for Paediatric Cardiology and Congenital Heart
Defects in Hamburg, Germany.
Feb 13, 2024 07:00 am ET
Ventripoint Welcomes Bart Hendriks as New Strategic Partnerships Executive to Accelerate European and Global Sales
Toronto, Ontario – TheNewswire - February 13, 2024 – Ventripoint Diagnostics Ltd.
("Ventripoint" or
the "Company"),
(TSXV:VPT) (OTC:VPTDF) is delighted to welcome Bart Hendriks as the
company's new Strategic Partnerships Executive, to accelerate adoption
of Ventripoint’s AI-powered, heart-scanning technology by hospitals
and clinics in Europe and around the world.
Feb 13, 2024 06:00 am ET
Ventripoint Announces Changes to The Board of Directors
Toronto, Ontario – February 13,
2024 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTCVPTDF) announces changes to the Board of Directors.
Feb 05, 2024 07:00 am ET
Ventripoint Begins 2024 with Leadership Change
Toronto, Ontario – TheNewswire - February 05, 2024 -
Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased
to announce the appointment of a new Interim CEO and President, Hugh
MacNaught, who has been serving on the Ventripoint Board of Directors
since 2020 and is a proven leader in biotech commercialization.
Feb 01, 2024 06:00 am ET
The Medical University of Vienna's Paediatric Heart Centre Purchases Ventripoint's AI-Powered Heart Imaging System
Toronto, Ontario – TheNewswire – February 1, 2024 - Ventripoint
Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF), a leader in using AI for
heart imaging, is pleased to announce The
Paediatric Heart Centre at the Medical University of Vienna has chosen
to adopt the VMS+ as its cardiac diagnostic tool.
Jan 29, 2024 06:00 am ET
The 2023 Year in Review
Toronto, Ontario – TheNewswire - January 29, 2024 -
Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to provide 2023 in
Review from the Ventripoint CEO and President, Dr. Alvira Macanovic.
Jan 21, 2024 07:10 pm ET
Dr. Luc Mertens, Head of Echocardiography at The Hospital for Sick Children, Joins Ventripoint's Clinical Advisory Board
Toronto, Ontario – TheNewswire - January 21,
2024 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce Dr. Luc
Mertens, one of Canada’s and the world’s top practitioners of
echocardiography, is joining Ventripoint’s Clinical Advisory
Board.
Jan 03, 2024 06:00 am ET
Ventripoint Whitepaper Distribution:
Dr. Alvira Macanovic outlines the
benefits of using AI to overcome sparse data and transform ultrasound
images into MRI-quality heart images
Dec 12, 2023 06:00 am ET
Dec 05, 2023 06:00 am ET
Ollie Hinkle Heart Foundation will Introduce Ventripoint's AI-Heart-Imaging Diagnostic Technology to America's Hospitals
Toronto, Ontario – TheNewswire - December 05, 2023 –
One of the United States’ leading foundations, the Ollie Hinkle
Heart Foundation (OHHF), has selected Ventripoint’s AI-powered
heart-imaging technology as one of three artificial intelligence
systems it will be presenting to U.S. hospitals.
Nov 29, 2023 06:30 pm ET
Ventripoint Diagnostics Reports Third Quarter 2023 Financial Results
Toronto, Ontario – The Newswire –
November 29, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint"
or the "Company"), (TSXV:VPT) (OTC:VPTDF) today reported financial
results for the third quarter ended September 30, 2023.
Nov 24, 2023 06:00 am ET
Ventripoint Announces Date and Timing for Release of Q3 2023 Financial Results and Webinar
Toronto, Ontario - The Newswire -
November 24, 2023 - Ventripoint Diagnostics
Ltd. ("Ventripoint"
or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce that it will release its
third-quarter financial results and Management Discussion &
Analysis for 2023 on Wednesday, November 29, 2023, after close of
market. Ventripoint will host a webinar/conference call at 11:00
a.m. (EST) on Friday, December 1, 2023, to discuss its Q3 2023
financial results and to provide an update on sales and marketing
activities. Details of the webinar/conference call are as
follows:
Nov 09, 2023 06:00 am ET
Ventripoint to Demonstrate AI-powered Heart Imaging Technology at The British Congenital Cardiac Association Annual Conference
Toronto, Ontario – TheNewswire - November 09, 2023 -
Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT) (OTC:VPTDF) is thrilled to announce it
will be showcasing its AI-powered heart-imaging technology at the
British Congenital Cardiac Association (BCCA) Annual Conference this
year in Bristol, UK from Nov. 13th to Nov.
14th
.
Nov 03, 2023 06:00 am ET
Ventripoint Diagnostics Reports Results of Annual General & Special Shareholders Meeting
Toronto, Ontario – The Newswire – November 3, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company") (TSXV:VPT) (OTC:VPTDF) is
pleased to announce the results of its annual general and special
meeting of shareholders held on November 1, 2023, in Toronto (the
"Meeting"). Shareholders voted in favour of each of the matters
considered at the Meeting, including electing each of Dr. George
Adams, Robert Hodgkinson, Hugh MacNaught, Fiona
Fitzgerald, Randy AuCoin, and Dr. Alvira Macanovic as directors of the
Company to hold office for the ensuing year, appointing MNP LLP as the
Company
Oct 24, 2023 06:00 am ET
Ventripoint to Hold Annual General Meeting of Shareholders on November 1, 2023
Toronto, Ontario - TheNewswire -
October 23, 2023 - Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Corporation”) (TSXV:VPT) (OTC:VPTDF) will hold its annual general and special meeting of
Shareholders (the “AGM”) on Wednesday, November 1, 2023 at 11:00
a.m. EST in a virtual-only format conducted via gotomeeting for the
following purposes:
Oct 12, 2023 06:00 am ET
Ventripoint AI Heart Imaging Technology To Be Presented at British Society of Echocardiography Annual Conference
Toronto, Ontario – The Newswire –
October 12, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) has
been accepted as a lead sponsor at the British Society of
Echocardiography’s (BSEcho) annual conference to demonstrate its use
of Artificial Intelligence to create MRI-quality model of the heart
from ultrasound images.
Oct 03, 2023 03:57 pm ET
Ventripoint Announces Appointment of Chief Finance Officer
Toronto, Ontario - TheNewswire - October 3, 2023 -
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce the
appointment of Mr. Jimmy Jeon as Chief Financial Officer (“CFO”)
of the Company. Mr. Jeon replaces Mr. Victor Hugo, who has served as
CFO since June 2020. The Company wishes to thank Mr. Hugo for
fulfilling that role and to express its appreciation for his
service.
Sep 28, 2023 06:00 am ET
Ventripoint's AI Heart Technology Takes Centre Stage In ITN Business "The Hidden Heart" Programme
Toronto, Ontario – TheNewswire –
September 28, 2023 - Ventripoint Diagnostics
Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF), a company using AI to create diagnostic heart
images, is thrilled to announce it will be
featured in an international news-style programme, “The Hidden
Heart”, made possible by the British Heart Foundation and ITN
Business.
Sep 15, 2023 06:00 am ET
Ventripoint to Sponsor DGPK Echo Advanced Workshop
Toronto, Ontario – The Newswire –
September 15, 2023 - Ventripoint Diagnostics
Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is thrilled to announce that it will be a sponsor
for the German Society for Pediatric Cardiology and Congenital Heart
Defects Echo Advanced Workshop being held on September 16th, 2023, in Bad
Oeynhausen. As a sponsor, Ventripoint will have the opportunity to
showcase the VMS+’s AI technology with 2D echo in a practical
hands-on session led by PD Dr. Kai Thorsten Laser.
Sep 13, 2023 06:00 am ET
Ventripoint to Sponsor 51st Annual Nordic Paediatric Cardiology Meeting
Toronto, Ontario – The Newswire –
September 13, 2023 - Ventripoint Diagnostics
Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is thrilled to announce that it will be a sponsor
for the prestigious 51st Annual Nordic Paediatric Cardiology Meeting
being held on September 13th-15th, 2023. The meeting will take place in
Helsinki with participants from all over the world.
Sep 08, 2023 06:00 am ET
Ventripoint Announced as Gold Sponsor for the 8th Annual Paediatric Echo Society Symposium
Toronto, Ontario – The Newswire –
September 08, 2023 - Ventripoint Diagnostics
Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is pleased to announce its participation as a Gold
Sponsor for the highly anticipated 8th Annual
Paediatric Echo Society Symposium. The event will take place in
Orlando, Florida on September 9th, 2023.
Aug 30, 2023 06:00 am ET
Ventripoint Diagnostics Reports Second Quarter 2023 Financial Results
Toronto, Ontario – The Newswire –
August 30, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF)
today reported financial results for the second quarter ended June 30,
2023 (www.sedar.ca).
Aug 25, 2023 06:00 am ET
Ventripoint Announces Date and Timing for Release of Q2 2023 Financial Results and Webinar
Toronto, Ontario – The Newswire –
August 25, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is
pleased to announce that it will release its second-quarter financial
results for 2023 on Tuesday, August 29, 2023, after close of market.
Ventripoint will host a webinar/conference call at 11:00 a.m. (EST)
on Wednesday, September 6, 2023, to discuss its Q2 2023 financial
results and to provide an update on sales and marketing activities.
Details of the webinar/conference call are as follows:
Aug 22, 2023 06:43 am ET
Ventripoint Welcomes Evelina London Children's Hospital as Newest VMS+ User
Toronto, Ontario – The Newswire –
August 22, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that Evelina London
Children’s Hospital (part of Guy's and St
Thomas' NHS Foundation Trust) is the newest user to adopt the VMS+ 3.0 system upgrade.
Aug 18, 2023 06:00 am ET
Ventripoint Unveils New Integrated Product with ASCEND Cardiovascular
Toronto, Ontario – TheNewswire –
August 18, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is
thrilled to announce that Ventripoint and ASCEND Cardiovascular, LLC
have developed a new integrated product. Today’s announcement
marks a significant milestone in Ventripoint’s commitment to the
collaboration between the two companies. ASCEND fits perfectly into
Ventripoint’s roadmap for innovation and is a key step in the
company’s mission to improve patient’s lives and become the
standard of care.
Aug 10, 2023 06:00 am ET
Ventripoint Announces Collaboration with Ascend Cardiovascular
Toronto, Ontario – The Newswire –
August 10, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is thrilled to announce that Ventripoint and
Ascend Cardiovascular, a leading provider of cardiovascular IT
solutions, have solidified a strategic collaboration. The two
companies have signed a letter of intent to explore joint research and
development initiatives, knowledge sharing, and combining efforts to
bring innovative AI-based solutions to the market.
Aug 02, 2023 06:00 am ET
Ventripoint Diagnostics to Attend 8th World Congress of Paediatric Cardiology and Cardiac Surgery
Toronto, Ontario – The Newswire –
August 2, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is thrilled to announce that it will be attending
the 8th World Congress of Paediatric Cardiology and Cardiac Surgery
in Washington, DC. This is the first time the congress will be held in
the continental United States. The conference will run from August
27th, 2023 – September 1st, 2023, in
Washington DC.
Jul 18, 2023 06:00 am ET
Ventripoint's VMS+ Purchased by Medical Center - University of Freiburg
Toronto, Ontario – The Newswire –
July 18, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF)
is pleased to announce that Freiburg Hospital
has chosen to adopt the VMS+ as its cardiac diagnostic tool.
Jul 11, 2023 06:00 am ET
Ventripoint to Sponsor Advanced Imaging 2023 in London, England
Toronto, Ontario – The Newswire –
July 11, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company") (TSXV:VPT); (OTC:VPTDF), is pleased to announce its participation as a
sponsor in Advanced Imaging 2023: Pericardial Disease, a prestigious
joint meeting sponsored by the British Society of Echocardiography and
the Royal Society of Medicine. The event is scheduled to take place
in London, England on July 18, 2023. The conference promises a
comprehensive overview of multimodality imaging and intervention for
pericardial disease. Ventripoint’s VMS+ solution provides physicians
with r
Jul 05, 2023 06:00 am ET
Ventripoint Diagnostics Makes Significant Sale to the Largest Heart Center in Germany
Toronto, ON -
TheNewswire - July 5, 2023 - Ventripoint
Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is pleased to announce that a VMS+ product has been purchased
by and is fully operstional in the Deutsches Herzzentrum der Charité
(DHZC), German Heart Center, in Berlin, Germany.
May 30, 2023 06:00 am ET
Ventripoint Receives European Union Medical Device Regulation Certification
Toronto, ON -
TheNewswire - May 30, 2023 - Ventripoint
Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is pleased to announce that it has successfully obtained
European Union Medical Device Regulation (EU MDR) certification for
its cardiac diagnostic system. This significant milestone further
underscores Ventripoint’s dedication to delivering state-of-the-art
diagnostic tools to healthcare professionals and improving patient
outcomes.
May 29, 2023 03:03 pm ET
Ventripoint Announces Date and Webinar Details Regarding First Quarter 2023 Financial Results
Toronto, ON - TheNewswire - May
29, 2023 - Ventripoint
Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is pleased to announce that it will release its
first-quarter, unaudited financial results for 2023 on Tuesday, May
30, 2023 at close of market.
May 17, 2023 02:27 pm ET
Ventripoint Issues Option Grants and Reports Exercise of Options
Toronto, ON -
TheNewswire - May 17, 2023 - Ventripoint
Diagnostics Ltd. (“Ventripoint” or the “Corporation”)
(TSXV:VPT) (OTC:VPTDF) announces that in January 2023 the Corporation granted an
aggregate of 1,115,000 options to directors, officers, employees,
contractors and consultants of the Corporation with an exercise price
of $0.30 and with terms of 10 (ten) years and vesting from immediately
to over 3 (three) years. Of these option grants, 850,000 were awarded
to directors and officers of the Corporation. In May 2023, the
Corporation granted an aggregate of 500,000 options to a consultant o
May 02, 2023 06:00 am ET
Ventripoint Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
Toronto, Ontario – The Newswire –
May 02, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) reported financial results for the fourth quarter
and full year ended December 31, 2022.
Apr 25, 2023 06:00 am ET
Ventripoint Announces Sponsorship of the 56th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
Toronto, Ontario – The Newswire –
April 25, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTCQB:VPTDF) is pleased to announce its sponsorship of the
56th Annual Meeting of the Association for European Paediatric and
Congenital Cardiology (AEPC) being held on April 26th-29th 2023 in
Dublin, Ireland.
Mar 16, 2023 06:05 am ET
Ventripoint Diagnostics Provides a Corporate Update
Toronto, Ontario – TheNewswire –
March 16, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to provide a corporate update on the
Company’s current status and the outlook for 2023.
Jan 02, 2023 10:57 am ET
Ventripoint Diagnostics Announces Dr. Alvira Macanovic as President and CEO
Toronto, Ontario – The Newswire –
January 2, 2023 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Corporation"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce the appointment of Dr.
Alvira Macanovic as President and CEO of the Corporation effective
January 1, 2023. Dr. George Adams will continue as
Executive-Chairman of the Corporation with responsibilities for new
applications, investor relations and strategic partnerships.
Dec 14, 2022 06:40 am ET
Ventripoint Diagnostics Provides a Corporate Update and Announces New Investor Relations Initiative
Toronto, Ontario – TheNewswire –
December 14, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to provide a corporate update.
Nov 30, 2022 06:00 am ET
Ventripoint Signs on Arc Group Medical LLC as Distributor in Florida Region
Toronto, Ontario – The Newswire –
November 30, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it has signed Arc
Group Medical LLC as a distributor for the US - Florida
reghion.
Nov 17, 2022 06:00 am ET
Ventripoint Appoints MediTek Lifesciences LLC as Distributor for California
Toronto, Ontario – The Newswire –
November 17, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) who’s mission is to improve cardiac diagnostic
for everyone, everywhere and especially for children, is pleased to announce that it has appointed MediTek
Lifesciences LLC. (Meditek) as a distributor for the USA-California
market. MediTek distributes products specific to cardiology research
and treatment centers throughout the State of California,
USA.
Nov 04, 2022 08:25 am ET
Ventripoint to Sponsor the Annual Meeting of the British Congenital Cardiac Association
Toronto, Ontario – TheNewswire –
November 4, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it will be a gold
sponsor for the 2022 Annual Scientific Meeting of the British
Congenital Cardiac Association (BCCA). Dr. Gregory Skinner, a
Clinical Advisor to the Company, will be giving a presentation that
will highlight the use of the VMS+3.0 in retrieving volumetric and
functional data for managing cardiac heart disease patients.
Oct 27, 2022 05:00 am ET
Ventripoint Diagnostics Provides a Corporate Update and Announces New Investor Relations Initiative
Toronto, Ontario – The Newswire –
October 27, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to provide a corporate update.
Oct 14, 2022 06:10 am ET
Ventripoint Diagnostics Exhibiting at the 2022 British Society of Echocardiography
Toronto, Ontario – TheNewswire –
October 14, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it will be hosting an
exhibit at the 2022 British Society of Echocardiography Conference in
London, England from October 14-15, 2022.
Aug 26, 2022 06:05 am ET
Ventripoint Announces Sponsorship for the European Society of Cardiology Congress 2022
Toronto, Ontario – TheNewswire –
August 26, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is excited to announce that it will be exhibiting
at the 70th European Society of Cardiology (ESC) Congress, which will be
held in Barcelona, Spain from August 26-29, 2022
Aug 10, 2022 07:35 am ET
Echocardiologists in Latin America Express Strong Interest in Ventripoint Whole Heart Analysis Products
Toronto, Ontario – TheNewswire –
August 10, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) participated in the 11th Cardiovascular
Imaging Conference (DIC) hosted by the Brazilian Society of Cardiology
(SBC), 29-31 July 2022, in Sao Paulo, Brazil.
Jun 29, 2022 06:05 am ET
Single Ventricle Congenital Heart Disease Study Launches at Leading Academic Medical Center using Ventripoint's VMS+3.0 Whole-Heart Analysis System
Toronto, Ontario – TheNewswire –
June 29, 2022 - Ventripoint
Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) is pleased to announce a
collaboration with Duke University School of Medicine in a new study
that analyzes single ventricle cardiac function in children. This will
be the first study to validate the VMS+3.0 in children with functional
single ventricles.
Jun 07, 2022 06:05 am ET
Ventripoint Exhibiting at the American Society of Echocardiography 33rd Annual Scientific Session
Toronto, Ontario – TheNewswire –
June 7, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it will be exhibiting
and attending as a sponsor (https://www.asescientificsessions.org/sponsors/) of the American Society of Echocardiography (ASE) 2022
Conference titled “Sound Waves in Seattle: Connecting the World”.
This is the 33rd annual scientific session of the ASE and is
being held in the Seattle Convention Center June 10-13, 2022.
May 17, 2022 06:30 am ET
Ventripoint Announces Sponsorship of the 55th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
Toronto, Ontario – TheNewswire –
May 17 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it will be a sponsor
for the 55th Annual Meeting of the Association for European Paediatric
and Congenital Cardiology (AEPC). The AEPC is a network of specialists
in the paediatric and congenital cardiology field who strive to
promote the sharing of information and resources within the community.
The AEPC is currently one of the largest global associations in the
cardiac field with over 1,000 paediatric cardiologists.
May 09, 2022 06:22 am ET
Ventripoint Hires Two Strategic Sales Account Managers for US, Europe, and UK Distribution
Toronto, Ontario – TheNewswire –
May 9, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that two new strategic
sales account managers have been hired to assist in the expansion of
global sales. Each account manager has the required skill set for
managing the sales and distribution of the VMS+ product on a global
scale.
May 03, 2022 06:05 am ET
Ventripoint Announces Sponsorship for the 2022 SickKids Echo Symposium
Toronto, Ontario – TheNewswire –
May 3, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it will be a sponsor
for the 2022 SickKids Echo Symposium. The topic of this year’s
symposium is introduction to cardiac anatomical (morphological)
abnormalities in congenital heart disease, how it relates to
echocardiographic imaging, and the use of echocardiographic imaging in
surgical decision-making in congenital heart disease. The event will
take place May 6-8 at the Hospital for Sick Children in Toronto,
Ontario. There is expec
Apr 27, 2022 06:00 am ET
Ventripoint Welcomes Dr. Jose Banchs as New Clinical Advisor
Toronto, Ontario – TheNewswire –
April 27, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is excited to have Dr. Jose Banchs join its Board
of Clinical Advisors.
Apr 19, 2022 06:00 am ET
Ventripoint Welcomes Dr. Howard Michael Leong-Poi as New Clinical Advisor
Toronto, Ontario – TheNewswire –
April 19, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to have Dr. Howard Michael Leong-Poi
join the Board of Clinical Advisors.
Apr 07, 2022 06:05 am ET
Ventripoint Signs on AngioConsult/Angiopro as European Distributor
Toronto, Ontario – TheNewswire –
April 7, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce it has signed Angiopro GmbH
as Ventripoint’s European Distributor for Ventripoint’s products
and engaged AngioConsult, their affiliated company to tailor the
marketing efforts to the different countries in the EU.
Apr 01, 2022 06:00 am ET
Ventripoint to Exhibit at the American College of Cardiology 71st Annual Scientific Session and Expo and Correction to North Equities Corp Grant of Stock Options
Toronto, Ontario – TheNewswire
– April 1, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) is pleased to announce that
it will be exhibiting at the 71st Annual Scientific Session and Expo,
hosted by the American College of Cardiology (ACC) between April 2-4,
2022, in Washington, D.C, United States.
Mar 21, 2022 06:25 am ET
Ventripoint Announces DTC Eligibility Approval in the U.S.
Toronto, Ontario – TheNewswire –
March 21, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT); (OTC:VPTDF),
a biotech diagnostic
company employing a leading Artificial
Intelligence (AI) approach known as Knowledge-Based Reconstruction
(KBR™) to create applications to monitor heart
disease, is pleased to announce that the
Company’s common shares are now eligible for electronic clearing and
settlement through the Depository Trust
Company (“DTC”) in the United States (“US”).
Mar 02, 2022 07:00 am ET
Ventripoint Hires Social Media Firm North Equities Corp.
Toronto, Ontario – TheNewswire –
March 2, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce it has engaged
Toronto-based marketing firm North Equities Corp. to provide marketing
services to the Company.
Mar 01, 2022 06:05 am ET
Ventripoint and at the Mazankowski Heart Institute to Collaborate to Conduct a World-First Study of the Changes in Cardiac Function during Pregnancy
Toronto, Ontario – TheNewswire –
March 1, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) will be supporting a world-first study on maternal
cardiovascular changes during pregnancy, which will be conducted at
the Mazankowski Alberta Heart Institute in Edmonton, Alberta,
Canada.
Feb 03, 2022 06:00 am ET
Ventripoint Announces Sponsorship for 24th Annual Canadian Society of Echocardiography Echo Weekend
Toronto, Ontario – TheNewswire –
February 3, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) is pleased to announce that
they will be a sponsor for the 24th Annual CSE
Echo Weekend. The conference will be held digitally February
4th-6th 2022 and will have the feature symposium “Unlocking the
Future of Hypertrophic Cardiomyopathy: From Pathogenesis and Imaging
to Treatment”.
Feb 02, 2022 06:00 am ET
Ventripoint Appoints Dr. Gregory Skinner to Board of Clinical Advisors
Toronto, Ontario - The Newswire -
February 2, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce
that Dr. Gregory Skinner has joined its Board of Clinical
Advisors.
Jan 27, 2022 06:50 am ET
Ventripoint Hires Iconic Investor Relations LLC to Provide Investor Relations Services
Toronto, Ontario – TheNewswire –
January 27, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) announces it has entered
into an investor relations agreement (the “IR Agreement”) with
Iconic Investor Relations LLC (“Iconic”). The IR Agreement is
for a term of twelve months commencing on January 20, 2022.
Jan 24, 2022 06:00 am ET
Ventripoint Successfully Completes European Commission QMS Certification Surveillance Audit
Toronto, Ontario - The Newswire -
January 24, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce
that is it has successfully completed a surveillance audit of its
quality assurance system under Medical Device Directive 93/42/EEC
(MDD), Annex II with no findings. This is the first surveillance
audit since Ventripoint’s last full recertification (see NR March 9,
2021).
Jan 21, 2022 07:35 am ET
Ventripoint Issues Option Grants and Reports Exercise of Options and Warrants
Toronto, Ontario – TheNewswire
– January 21, 2022 - Ventripoint
Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”)
(TSXV:VPT), (OTC:VPTDF) announces that on January
20, 2022 the Corporation granted an aggregate of 1,725,000 options to
directors, officers, employees, contractors and consultants of the
Corporation with an exercise price of $0.40 and with terms from one to
ten years and vesting from immediately to over 3 years. Of these
option grants, 500,000 were awarded to directors and officers of the
Corporation. The Corporation now has 4,096,590 options available for
future grants u
Jan 07, 2022 06:00 am ET
Ventripoint Announces Up-Listing to OTCQB Venture Market
Toronto, Ontario - The Newswire -
January 7, 2022 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is
pleased to announce the Company has received official notification
from OTC Markets to up-list to the OTCQB tier effective as of
January 7, 2022. The Company will trade on the OTCQB exchange under
symbol “VPTDF”; the Company’s common shares will continue to trade on
the Toronto Securities Venture Exchange under the symbol
“VPT”.
Dec 29, 2021 06:00 am ET
Ventripoint Successfully Renews QMS Certification
Toronto, Ontario - The Newswire -
December 29 2021 - Ventripoint
Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is
pleased to announce that is it has successfully completed the Medical
Device Single Audit Program (MDSAP) re-certification for its Quality
Management System (QMS) under ISO 13485:2016 regulations and the FDA
Quality System Regulations, which facilitates continued design,
manufacturing, installation and servicing of its products in Canada
and the United States.
Dec 21, 2021 06:30 am ET
Ventripoint Expands United Kingdom Marketing with New Distribution Partner CardioLogic
Toronto, Ontario – TheNewswire –
December 21, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce a distributor partnership
with CardioLogic Ltd. (www.cardiologic.co.uk).
Dec 20, 2021 06:05 am ET
Ventripoint Appoints Randy AuCoin to Board of Directors
Toronto, Ontario – TheNewswire –
December 20, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that Randy AuCoin has
joined the Ventripoint Board of Directors.
Dec 06, 2021 05:00 am ET
Ventripoint Receives Additional Funding to Develop Next Generation of the VMS+, Whole-Heart Analysis System
Toronto, Ontario - The Newswire -
December 6, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to announce
that Ventripoint has received additional advisory services and up to
$107,000 in research and development funding from the National
Research Council of Canada Industrial Research Assistance Program (NRC
IRAP). This new funding is in addition to the up to $120,000 that has
already been approved.
Nov 29, 2021 06:10 am ET
Ventripoint Applauds the US Government for Establishing an Additional Payment to Doctors for Analyzing 3D Heart Scans
Toronto, Ontario – TheNewswire –
November 29, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased that the U.S. Department of Health and
Human Services (HHS) through CMS (Centers for Medicare & Medicaid
Services) has approved a new compensation for doctors to analyze 3D
echocardiograms.
Nov 24, 2021 06:25 am ET
Ventripoint Selected by Life Sciences Ontario as 2021 Success Story
*** LSO Initiates Campaign to Inform Ontario MPPs of
Activity within the Sector ***
Nov 22, 2021 06:05 am ET
Ventripoint Provides Corporate Update on Market Adoption of VMS+ Whole-heart Analysis System
*** On track to Achieve Target of having 25-30
hospitals with VMS+ by year end ***
Nov 09, 2021 06:30 am ET
Ventripoint Passes Audit of Manufacturing Facility for Canadian and US Markets
Toronto, Ontario – TheNewswire –
November 9, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) is pleased to announce that
they have successfully completed a semi-annual follow up inspection of
their manufacturing facility by a Nationally Recognized Testing
Laboratory (NRTL).
Oct 25, 2021 06:05 am ET
Ventripoint Appoints Fiona Fitzgerald to the Board of Directors
Toronto, Ontario – TheNewswire –
October 25, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce Fiona Fitzgerald has joined
the Board of Directors of the Company.
Oct 21, 2021 06:10 am ET
Ventripoint Installs VMS+ 3.0 Unit at East Midlands Congenital Heart Centre
Toronto, Ontario – The Newswire –
October 21, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that the East Midlands
Congenital Heart Centre in Leicester, UK has received the VMS+3.0 unit.
Oct 20, 2021 07:10 am ET
Ventripoint Diagnostics Ltd. Announces Closing of Upsized Bought Deal Offering of Units
Toronto, Canada –
TheNewswire - October 20,
2021 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”) (TSXV:VPT),
(OTC:VPTDF), is pleased to
announce that has closed its previously announced upsized bought-deal
public offering (the “Offering”) including full exercise of the
over-allotment option.
Oct 13, 2021 11:40 am ET
Ventripoint Diagnostics Ltd. Announces Filing of Second Amended and Restated MD&A
Toronto, Canada – TheNewswire -
October 13, 2021 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the “Company”)
(TSXV:VPT), (OTC:VPTDF), announces that as a result
of a review by staff of the Ontario Securities Commission
(“OSC”) it is issuing the following press release to clarify its
previous disclosure. The Company has filed a second amended and
restated management’s discussion and analysis for the three and six
month period ended June 30, 2021 (the “Second Revised MD&A”).
Oct 01, 2021 02:30 pm ET
Ventripoint Diagnostics Ltd. Announces Filing of Amended and Restated Interim Financial Statements and MD&A
Toronto, Canada - TheNewswire – October 1, 2021 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”)
(TSXV:VPT) (OTC:VPTDF), announces that it has filed amended and restated
unaudited condensed consolidated interim financial statements for the
three and six months ended June 30, 2021 (the "Amended
Statements") and related amended and restated management's
discussion and analysis. The Amended Statements were required to
correct accounting errors, which were identified during an internal
review for the purposes of completing the recently announced
financing.
Sep 28, 2021 08:25 am ET
Ventripoint Diagnostics Ltd. Announces Upsize to Previously Announced Bought Deal Offering of Units to $7 Millon
Toronto, Canada –
TheNewswire - September
28, 2021 – Ventripoint
Diagnostics Ltd. (“Ventripoint” or the “Company”)
(TSXV:VPT), (OTC:VPTDF), is pleased to announce it
has upsized its public offering (the “Offering”) of units
(the “Units”) to $7 million from $5 million at a price of $0.52 per
Equity Unit. If the Agent’s Option (as defined below) is exercised
in full, the aggregate gross proceeds of the Offering will be
approximately $8,055,060.
Sep 28, 2021 08:24 am ET
IIROC Trading Resumption - VPT
VANCOUVER, BC, Sept. 28, 2021 /CNW/ - Trading resumes in:
Sep 27, 2021 04:04 pm ET
IIROC Trading Halt - VPT
VANCOUVER, BC, Sept. 27, 2021 /CNW/ - The following issues have been halted by IIROC:
Sep 27, 2021 03:55 pm ET
Ventripoint Diagnostics Ltd. Announces $5 Million Bought Deal Offering of Units
Toronto, Canada -
TheNewswire – September
27, 2021 – Ventripoint
Diagnostics Ltd. (“Ventripoint” or the “Company”)
(TSXV:VPT) (OTC:VPTDF), is pleased to announce that is has entered into
an agreement with Leede Jones Gable Inc. and Stifel GMP as the
underwriters and
co-bookrunners (the “Underwriters”), pursuant to which the
Underwriters have agreed to purchase, on a bought-deal basis,
9,620,000 units (the “Units”) for gross proceeds to the Company of
$5,002,400 (the
“Offering”) at a price of $0.52 per Unit.
Sep 17, 2021 02:32 pm ET
Ventripoint Issues Option Grants to Consultant
Toronto, Ontario – TheNewswire
– September 17, 2021 - Ventripoint
Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”) (TSXV:VPT) (OTC:VPTDF) announces that
on September 15, 2021 the Board of Directors approved the granting of
an aggregate of 300,000 options to a consultant of the Corporation at
an exercise prices from $0.50 to $.55 for a term of one years and
vesting from immediately to over 9 months. The Corporation now has
6,006,590 options available for future grants under the Stock Option
Plan as approved by shareholders at the last Special and Annual
General Meeting on August 9, 20
Sep 15, 2021 06:20 am ET
Ventripoint Provides Update on Clinical Studies
Toronto, Ontario – TheNewswire –
September 15, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has provided an
update on clinical studies using the VMS+ 3.0.
Sep 14, 2021 05:00 am ET
Ventripoint Provides Update on Growth Initiatives and Sales
Toronto, Ontario - The Newswire -
September 14, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) has provided an update on recent
milestones including sales, marketing, COVID-19-related developments
and market outreach.
Sep 07, 2021 03:35 pm ET
Ventripoint Issues Option Grants to Consultants and Reports Options Exercise
Toronto, Ontario – TheNewswire
– September 7, 2021 - Ventripoint
Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”) (TSXV:VPT) (OTC:VPTDF) announces that
on September 3, 2021 the Board of Directors approved the granting of
an aggregate of 300,000 options to consultants of the Corporation at
an exercise price of $0.40 for a term of one to two years and vesting
from immediately to over 9 months. The Corporation now has 6,331,590
options available for future grants under the Stock Option Plan as
approved by shareholders at the last Special and Annual General
Meeting on August 9, 2021.
Sep 03, 2021 08:35 am ET
Ventripoint Reports Second Quarter 2021 Financial Statements and MD&A
Toronto, Ontario – TheNewswire –
September 03, 2021 - Ventripoint Diagnostics
Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) is pleased to announce that
it has filed its interim unaudited Financial Statements and Management
Discussion and Analysis (MD&A) for the second quarter, ending June
30, 2021. These filings can be viewed on the Company’s profile at
www.SEDAR.com
Aug 09, 2021 07:40 am ET
Ventripoint Announces Patent Application for Improved Heart Analysis
Toronto, Ontario – TheNewswire –
August 09, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has filed an international patent application
under the Patent Cooperation Treaty (PCT) to protect Ventripoint’s
recent novel improvements to its cardiac measurement technology.
Ventripoint is a pioneer in application of artificial intelligence
(AI) to heart analysis and this latest application strengthens the
company’s intellectual property position and coverage for the
Ventripoint’s flagship products. With this one international
patent application, Vent
Jul 05, 2021 07:07 am ET
Ventripoint Engages Digital257 for Social Media and Investor Relations Services
Toronto, Ontario – TheNewswire –
July 5, 2021 - Ventripoint Diagnostics Ltd.
(" Ventripoint " or the
" Company "), (TSXV:VPT ) ; (OTC:VPTDF) is pleased to announce
that it has engaged Digital257 Technologies
Inc. to provide investor relations and social media services pursuant
to a consulting agreement dated June 2, 2021.
Jul 02, 2021 02:07 am ET
Ventripoint Issues Option Grants to Consultants and a Director of the Corporation
Toronto, Ontario – TheNewswire
– July 2, 2021 - Ventripoint Diagnostics
Ltd. (“ Ventripoint ” or the “ Corporation ”) (TSXV:VPT) (OTC:VPTDF) announces that
on July 1, 2021 the Board of Directors approved the granting of an
aggregate of 850,000 options to consultants and a Director of the
Corporation at an exercise price of $0.30 for a term of one year and
vesting from immediately to over 9 months. The Corporation now has
1,078,685 options available for future grants under the Stock Option
Plan as approved by shareholders at the last Special and Annual
General Meeting on December 14, 2020.
May 21, 2021 06:05 am ET
Ventripoint Announces Sponsorship for the 54th Annual Meeting of the Association of European Paediatric and Congenital Cardiology
Ventripoint Also Provides a Financial Update
May 06, 2021 06:05 am ET
Ventripoint update on its Financial Status and on Warrant and Option Exercises
Toronto, Ontario – TheNewswire –
May 6, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to provide this update on its financial
status and the exercises of warrants and options since the last update
(see NR March 3, 2021).
May 04, 2021 06:05 am ET
Ventripoint Receives Government Funding to Advance Development of Next Generation of VMS+
Toronto, Ontario – TheNewswire –
May 4, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is excited to announce that it is receiving
advisory services and research and development funding of up to
$120,000 from the National Research Council of Canada Industrial
Research Assistance Program (NRC IRAP) to further enhance cardiac
measurement capabilities of the VMS+. This funding is a continuation
of a previously successful NRC IRAP-funded project that resulted in
the development of VMS+3.0.
Apr 27, 2021 08:36 am ET
IIROC Trading Resumption - VPT
VANCOUVER, BC, April 27, 2021 /CNW/ - Trading resumes in:
Apr 27, 2021 05:04 am ET
Ventripoint Collaborates with GE Healthcare to Bring More Functionality to its Cardiac Ultrasound Devices
Toronto, Ontario - The Newswire
- April 27, 2021 -
Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT) (OTC:VPTDF) announces the Company has
entered into a collaboration with GE Healthcare.
Apr 26, 2021 02:03 pm ET
IIROC Trading Halt - VPT
VANCOUVER, BC, April 26, 2021 /CNW/ - The following issues have been halted by IIROC:
Apr 20, 2021 07:04 am ET
Ventripoint Attends 23rd Annual Canadian Echo Weekend and Grants Stock Options
Toronto, Ontario – TheNewswire –
April 20, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) attended the 23rd Annual
Canadian Echo Weekend – 2021 Digital Edition, which was organized by
the Canadian Society of Echocardiography (CSE).
Apr 19, 2021 06:04 am ET
Ventripoint Extends Patent Portfolio with Foundational U.S. Provisional Patent Filing of Heart Motion Tracking Technology
Toronto, Ontario - The Newswire -
April 19, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) has filed a U.S.
provisional patent application for its novel cardiac measurement
approach.
Apr 15, 2021 06:04 am ET
Ventripoint Announces Sponsorship for the 2021 Canadian Society of Echocardiography Weekend Conference
Toronto, Ontario – TheNewswire –
April 15, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce its sponsorship of the 2021
Canadian Society of Echocardiography (CSE) Virtual Echo Weekend
Conference to be held this weekend on April 17-18, 2021.
Apr 13, 2021 06:04 am ET
Ventripoint Diagnostics Begins Publication of Case Studies Showing Meritorious Use of the VMS Heart Analysis System
Toronto, Ontario – TheNewswire –
April 13, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has published its first case study of the
meritorious use of the Ventripoint VMS whole-heart analysis system
(https://www.ventripoint.com/whitepapers-case-studies) in routine
clinical practice.
Mar 16, 2021 06:03 am ET
Ventripoint JV Begins Process to have Heart Analysis System Certified for use in COVID Patients in China
Toronto, Ontario – TheNewswire –
March 16, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) announces that its partner,
Yutian Medical Shanghai Inc. (“Yutian”), has reported Chinese guidelines for the
diagnosis and treatment of COVID-19 patients now require the
monitoring of right-ventricular function by non-invasive techniques.
Mar 09, 2021 06:03 am ET
Ventripoint Passes Regulatory Inspection of Manufacturing Facility and Audit of Quality Assurance System
Toronto, Ontario – TheNewswire –
March 9, 2021 - Ventripoint
Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) is pleased to announce the
Company has completed another successful NRTL inspection of their
manufacturing facility for the manufacture of the VMS+ 3.0.
Mar 03, 2021 12:03 pm ET
Ventripoint Announces Extension Warrants from March 23, 2021 to May 23, 2021
Toronto, Ontario – TheNewswire –
March 3, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) announces that it has
applied to the TSX Venture Exchange (the “TSXV”) to extend
the expiry date of 10,496,938 common share purchase warrants issued by
the Corporation (the “Warrants”) in connection with a private
placement financing on March 23, 2017 and previously extended to March
23, 2021. This Company will extend the expiry date by 60 days to May
23, 2021. The Warrants to be amended do not include any warrants
issued to finders or agents. No other term
Mar 03, 2021 06:03 am ET
Ventripoint Diagnostics Receives Additional Innovation Assistance Program Funding and Updates Warrant Exercises
Clean Balance Sheet
and Two Years of Cash
Mar 02, 2021 06:03 am ET
Ventripoint JV Begins Training Chinese Cardiologists in Heart Analysis System and Achieves Milestone of First Commercial Sales
Toronto, Ontario – TheNewswire –
March 2, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) is pleased to announce that
its partner, Yutian Medical Shanghai Inc.
(“Yutian”), has reported a successful engagement
with key opinion leaders in the echocardiography sector in China. A
training session in the use of the QAS™ (VMS™ in China) has been
conducted in China for approximately 60 echocardiologists. The
session was offered in cooperation with one of the leading University
Hospitals in China and organized by the China Medical Association,
Intensive
Feb 24, 2021 02:02 am ET
Correction - Ventripoint Diagnostics Issues Shares in Final Payment of Debenture Interest
Toronto, Ontario – TheNewswire –
February 24, 2021 - Ventripoint
Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT) (OTC:VPTDF) announces correction to
February 10, 2021 press release. The Company
has issued an aggregate of 96,961 shares, rather than the 131,430
shares previously announced, for the
final interest payment of $23,274 on Convertible
Debentures issued by the Company on February 6, 2020, replacement
Convertible Debentures issued the same date, and Convertible
Debentures issued September 11, 2020. The shares will be issued at a
deemed price of $.24 per share. Two direct
Feb 23, 2021 06:02 am ET
Ventripoint Heart Analysis System to be used at the Stollery Children's Hospital to Study Atrial Dysfunction in Children
Toronto, Ontario – TheNewswire –
February 23, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is announcing the
commencement of a new clinical study to measure atrial volumes and
ejection fractions in children with suspected valvular disease. The
study is being conducted by cardiologists in the Department of
Pediatrics, Division of Pediatric Cardiology at the University of
Alberta in collaboration with the Mazankowski Heart Institute and
Stollery Children’s Hospital.
Feb 16, 2021 05:02 am ET
Ventripoint Advances Sales, Marketing, and Distribution Partnership in the Largest Market in World for Heart Disease: China
Toronto, Ontario - The Newswire -
February 16, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is
pleased to provide a corporate update on sales and marketing
activities in China by our joint-venture partner Yutian Medical
Shanghai Inc. (“Yutian”).
Feb 10, 2021 02:02 am ET
Ventripoint Diagnostics Issues Shares in Final Payment of Debenture Interest
Toronto, Ontario – TheNewswire –
February 10, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"),
(TSXV:VPT); (OTC:VPTDF) announces the issuance of
an aggregate of 131,430 shares for the final
interest payment of $23,274 on Convertible Debentures issued by the
Company on February 6, 2020, replacement Convertible Debentures issued
the same date, and Convertible Debenture issued September 11, 2020.
All debentures have been converted to common shares of the Company,
and interest is calculated to the date of conversion. The shares
will be issued at a deemed price based on the c
Feb 09, 2021 10:02 am ET
Ventripoint Diagnostics Upgrades Investor Relations Webpage
Toronto, Ontario – TheNewswire –
February 9, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) has released the company’s
new Investor Relations (IR) section on the company’s website.
Feb 08, 2021 08:02 am ET
Correction: Ventripoint Accelerated Expiry Date of Warrants
Toronto, Ontario - The Newswire -
February 8, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) wishes to correct the
news release of February 3, 2021.
Feb 08, 2021 08:02 am ET
Ventripoint Issues Option Grants
Toronto, Ontario - TheNewswire - February 8, 2021
- Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Corporation”, TSXV:VPT) (OTC:VPTDF) announces that on February
5, 2021 the Board of Directors approved the granting of 900,000
options to consultants at an exercise price of $0.25 for a term of 2-5
years and vesting from immediately to 1 year. The Corporation now
has 135,000 options available for future grants under the Stock Option
Plan as approved by shareholders at the last Special and Annual
General Meeting on December 14, 2020.
Feb 05, 2021 05:02 am ET
Ventripoint Hires MarketSmart Communications to Provide Investor Relations Services
Toronto, Ontario - The Newswire -
February 5, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) announces it has entered into an investor relations agreement with
MarketSmart Communications Inc. pursuant to which MarketSmart will
provide investor relations (IR) services to Ventripoint. The IR
agreement is for an initial term of six months commencing on February
5th,
2021, with an option for renewal. Either party may terminate the
agreement for any reason, with or without cause, on 15-days written
notice to the other.
Feb 03, 2021 05:02 am ET
Jan 27, 2021 09:01 am ET
Ventripoint Issues Option Grants and Exercises
Toronto, Ontario - TheNewswire - January 27, 2021
- Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Corporation”, (TSXV:VPT) (OTC:VPTDF) announces that on January 19, 2021 the Board of Directors
approved the granting of 825,000 options to consultants at exercise
prices from $0.135 to $0.20 for a term of 1 year, with vesting over 4 months. The
Corporation is also announcing that 900,000 options with an exercise
price of $0.10 have been exercised in the January 2021. The
Corporation now has 1,567,435 options available for future grants
under the Stock Option Plan as approved by sharehold
Jan 18, 2021 05:01 am ET
Ventripoint Diagnostics Issues Shares in Payment of Consulting Fees
Toronto, Ontario – TheNewswire –
January 18, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) announces it will issue an aggregate of
666,666 shares to a consultant for $60,000 in
consulting fees at a deemed price of $0.09 per share, which was the
closing share price on September 30, 2020 and December 31, 2020 when
the fees were due and payable.
Jan 13, 2021 05:01 am ET
Jan 13, 2021 03:01 am ET
Ventripoint Issues Option Grants
Toronto, Ontario – TheNewswire - January 13, 2021 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”),
(TSXV:VPT) & (OTC:VPTDF) announces the granting 100,000 options to each of the
Directors of the Corporation at an exercise price of $0.10 for a term
of 10 years with 25% vesting immediately and 25% vesting each year for
3 years thereafter. In addition, 1,410,000 option have been granted to
employees and consultants at an exercise price of $0.10 for term from
1 to 10 years, with variable vesting schedules. The Corporation now
has 1,542,435 options available for future gran
Jan 11, 2021 05:01 am ET
Ventripoint Expands to Address the Needs of Companion Animals
Toronto, Ontario - The Newswire -
January 11, 2021 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) announces that it has entered into a Collaboration Agreement
with the Veterinary Hospital at the North Carolina State University
(NCSU) to test and evaluate the use of the VMS+
in echocardiography of canines with the goal of expanding this
technology to all animals.
Jan 04, 2021 06:01 am ET
Kings College London Receives VMS+3.0 Ventripoint Whole Heart Analysis System
First VMS+3.0 in UK and Seventh
Hospital to Adopt the Latest VMS Technology
Dec 15, 2020 07:12 am ET
Ventripoint Diagnostics Reports Results of Annual General & Special Shareholders Meeting
Toronto, Ontario – TheNewswire –
December 15, 2020 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) held its Annual General & Special Shareholders
meeting via conference call yesterday, December 14, 2020.
Dec 14, 2020 07:12 am ET
Ventripoint Diagnostics Receives Loan from FedDev Regional Relief and Recovery Fund and Reminds Shareholders about Annual General Meeting Today
Toronto, Ontario – TheNewswire –
December 14, 2020 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) announces it has received an interest-free loan
for $163,000 from the Federal Economic
Development Agency for Southern Ontario Regional
Relief and Recovery Fund. The loan is to be
used to assist the Company in meeting its financial obligations
related to fixed operating costs. The loan is repayable starting in
April 2023 in equal monthly installments over a 5-year period with the
final payment in 2028.
Dec 10, 2020 07:12 am ET
Ventripoint Diagnostics Receives Wage Subsidy
Toronto, Ontario – The Newswire –
December 10, 2020 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) announces that it is receiving an additional
temporary wage subsidy of up to $115,408 as part of the National Research Council
of Canada Industrial Research Assistance Program’s (NRC IRAP)
Innovation Assistance Program (IRAP IAP).
Nov 26, 2020 02:11 am ET
Ventripoint Diagnostics Issues Shares in Payment of Debenture Interest, Consulting Fees and DSU Exercise
Toronto, Ontario – TheNewswire –
November 26, 2020 - Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) announces it will issue an aggregate of
233,365 shares for the payment of $23,337 of
interest for the three months ended November 6, 2020, on Convertible
Debentures issued by the Corporation on February 6, 2020 and
Convertible Debentures issued the same date as part of a replacement
of convertible debentures. Pursuant to the Convertible Debentures, the
shares will be issued at a deemed price of $0.10 per share. Two
Directors of the Company will receive a
Nov 05, 2020 05:11 am ET
Canada's Largest Cardiac Centre Receives VMS+3.0 Ventripoint Whole Heart Analysis System
Improved cardiac imaging system gaining market adoption with leading medical centers
Nov 03, 2020 06:11 am ET
Ventripoint Engages Oak Hill Financial to Provide Investor Relations Services and Approval of Warrant Amendment
Toronto, Ontario – TheNewswire – November 3, 2020 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"),
(TSXV:VPT) (OTC:VPTDF) is
pleased to announce that, subject to TSXV approval, it has engaged
Oak Hill Financial Inc. ("Oak Hill"), a Toronto-based
investor relations firm, to provide market awareness and investor
relations services to the Company in compliance with TSXV policies.
Jonathan Robinson is a partner with Oak Hill and will be responsible
for activities related to Ventripoint.
Oct 09, 2020 02:10 am ET
Ventripoint Makes Application to Amend Warrrants
Toronto, Ontario – The Newswire - October 09, 2020-
Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT) (OTC:VPTDF) announces that it has made an application to the TSX
Venture Exchange (the “TSXV”) to amend the exercise price
of common share purchase warrants originally
issued on October 2, 2019.
Oct 08, 2020 06:10 am ET
Ventripoint Installs Whole Heart Analysis System in MD Anderson Cancer Center in Houston
Toronto, Ontario – The Newswire - October 08, 2020 -
Ventripoint Diagnostics Ltd. ("Ventripoint" or
the "Company"), (TSXV:VPT); (OTC:VPTDF) is
pleased to announce that it has remotely installed the latest version
of its whole-heart analysis system (VMS+3.0) in the University of Texas MD Anderson Cancer Center. It is one of
the world's most respected centers devoted exclusively to cancer
patient care, research, education and prevention as recorded by being
ranked one of the top two hospitals for cancer care every year for the
last 30 years.
Sep 30, 2020 06:09 am ET
Ventripoint Announces Appointment to the Board of Directors and Option Grants
Toronto, Ontario – TheNewswire - September 30, 2020 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”),
(TSXV:VPT) & (OTC:VPTDF) is pleased to announce, Mr. Hugh MacNaught has been appointed as
a Director of the Corporation.
Sep 28, 2020 05:09 am ET
Ventripoint Remotely Installs Whole Heart Analysis System in Major European Hospital
Toronto,
Ontario -
TheNewswire -
September 28,
2020
- Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is pleased to
announce that it has remotely installed the latest version of its
whole-heart analysis system (VMS+3.0) in a Erasmus-Sophia University
Medical Center (Erasmus MC) in Rotterdam. This is the first time in
the Company’s history, a system has become operational without an
installation team going to the hospital to integrate it into
hospital’s infrastructure. It is also the first VMS+3.0 unit which
has been placed in Europe.
Sep 25, 2020 07:09 am ET
Correction: Options at exercise price of $0.10. Ventripoint Engages Torrey Hills Capital to Provide Investor Relations Services
Toronto,
Ontario –
The Newswire -
September 25, 2020
- Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) is pleased to announce that, subject to TSXV
approval, it has engaged San Diego Torrey Hills
Capital, Inc. ("Torrey Hills Capital"), a Rancho Santa Fe,
California based investor relations firm, to provide market awareness
and investor relations services to the Company in compliance with TSXV
policies. Cliff Mastricola is the principal of Torrey Hills Capital
and will be responsible for activities related to Ventripoint.
Sep 25, 2020 07:09 am ET
Correction: Options at exercise price of $0.10. Ventripoint Engages Torrey Hills Capital to Provide Investor Relations Services
Toronto,
Ontario –
TheNewswire -
September 25, 2020
- Ventripoint Diagnostics Ltd.
("Ventripoint" or the "Company"), (TSXV:VPT) is pleased to announce that, subject to TSXV
approval, it has engaged San Diego Torrey Hills
Capital, Inc. ("Torrey Hills Capital"), a Rancho Santa Fe,
California based investor relations firm, to provide market awareness
and investor relations services to the Company in compliance with TSXV
policies. Cliff Mastricola is the principal of Torrey Hills Capital
and will be responsible for activities related to Ventripoint.
Sep 25, 2020 05:09 am ET
Sep 24, 2020 04:19 pm ET
IIROC Trading Resumption - VPT
VANCOUVER, BC, Sept. 24, 2020 /CNW/ - Trading resumes in:
Sep 23, 2020 12:09 pm ET
Ventripoint To Resume Trading at the Market Opening Friday, September 25, 2020
Toronto,
Ontario –
TheNewswire -
September 23,
2020- Ventripoint Diagnostics
Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) is pleased to announce that it has been
advised by the TSXV Exchange that the Company’s shares will resume
trading at the opening of the market on Friday, September 25,
2020.
Sep 15, 2020 06:09 am ET
Ventripoint Provides Corporate Update and Enters Review by TSXV to Resume Trading
Toronto, Ontario – TheNewswire - September 15, 2020 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”),
(TSXV:VPT) is pleased to
provide a corporate update and the initiation of a “resumptive
review” by the TSXV Exchange to lift the trading halt, which was
requested by the Company on December 12, 2019. It is anticipated
this review will take only a few days and trading of the Company’s
stock will resume shortly.
Sep 14, 2020 07:09 am ET
Ventripoint Announces Closing of Second Tranche of Non-Brokered Secured Convertible Debenture Unit Private Placement
Toronto, Ontario - TheNewswire - September 14, 2020 - Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Corporation”,
(TSXV:VPT) is pleased to
announce that it has closed the second and final
tranche of its previously announced non-brokered private placement of
secured convertible debenture (the “Offering”). The
second tranche of $495,000 along with the first tranche of $725,000
completes the full Offering for gross proceeds of $1,220,000.
Jun 03, 2020 06:06 am ET
Ventripoint Announces Appointment of Chief Finance Officer
Toronto, Ontario – TheNewswire - June 3, 2020
– Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”),
(TSXV:VPT) wishes to announce that Victor Hugo has
been appointed the CFO of Ventripoint pursuant to a consulting
agreement with Marrelli Support Services Inc.
May 29, 2020 08:05 am ET
Ventripoint Announces Postponement of First Quarter Filings
Toronto, Ontario – TheNewswire - May 29, 2020 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Corporation”),
(TSXV:VPT) wishes to announce that the Company is postponing the
reporting of its first quarter Financial Statements and Management’s
Discussion and Analysis (“MD&A”) as a result of delays caused
by the COVID-19 pandemic. The Company aims to file these documents by
the end of June 2020 under the terms of the 45-day extension announced
by the Ontario Securities Commission under the “Ontario Instrument
51- 502”, dated March 23, 2020. The Company ratifies that management
and th
Feb 10, 2020 07:02 am ET
Ventripoint Announces Closing of First Tranche of Non-Brokered Secured Convertible Debenture Unit Private Placement and Exchange of Existing Debentures and Repricing and Extension of the Associated Wa
Toronto, Ontario – TheNewswire - February 10, 2020 – Ventripoint
Diagnostics Ltd. (“Ventripoint” or the
“Corporation”),
(TSXV:VPT) is pleased to
announce that it has closed the first tranche of
its previously announced non-brokered private placement of secured
convertible debenture units for gross proceeds of $725,000 and the
exchange of existing debentures and repricing
and extension of the associated warrants. The
Corporation intends to complete the previously announced non-brokered
private placement with total gross proceeds of up to CDN$1,220,000
(the “Offering”) of debenture units of th
Jan 28, 2020 08:01 am ET
Ventripoint Provides Corporate Update and Announces $1,220,000 Non-Brokered Debenture Unit Private Placement and Exchange of Existing Debentures and Repricing and Extension of the Associated Warrants
Toronto, Ontario – TheNewswire - January 28, 2020 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”, (TSXV:VPT)
is pleased to announce stakeholders have stepped
forward to finance the commercialization of its robust technology. The
past month there has been a restructuring of the Company to focus on
manufacturing and sales. The Company is
pleased to provide a Corporate update.
Dec 19, 2019 02:12 am ET
Ventripoint Clarifies News Release of December 17, 2019
Toronto, Ontario – TheNewswire - December 19,
2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the
“Company”) (TSXV:VPT)
(OTC:VPTDF) wishes to clarify the
news release of December 17, 2019.
Dec 18, 2019 02:12 am ET
Ventripoint Diagnostics Provides Corporate Update
Toronto, Ontario – TheNewswire - December
18, 2019 –
Ventripoint Diagnostics Ltd. (“Ventripoint”
or the “Company”) (TSXV:VPT)
(OTC:VPTDF) announces that the Board of
Directors of the Company had deemed the Company was no longer a going
concern and elected to put the Company into receivership.
Subsequently, Dr. Don Segal, David Willis, Dr. Alan Rabinowitz have
resigned as Directors of the Company. Justin Leuschner has resigned
as a Director and CEO of the Company. Ellen Briant has resigned as
CFO. Desmond Hirson has resigned as the CTO and will be available to
the Company as a consultant. T
Dec 12, 2019 07:41 am ET
IIROC Trading Halt - VPT
VANCOUVER, Dec. 12, 2019 /CNW/ - The following issues have been halted by IIROC:
Nov 29, 2019 06:11 am ET
Ventripoint Diagnostics to Exhibit at Radiological Society of North America's 105th Scientific Assembly and Annual Meeting
Toronto, Ontario – TheNewswire - November 29,
2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the
“Company”) (TSXV:VPT)
(OTCQB:VPTDF) is exhibiting for
the first time at the Radiological Society of North America’s
105th Scientific Assembly and Annual Meeting
(RSNA 2019), held in Chicago’s McCormick Place from December 1-6.
Join us at Booth #1133.
Nov 04, 2019 06:11 am ET
Ventripoint Announces Appointment of Justin Leushner as CEO and Changes to the Board of Directors
Toronto, Ontario – TheNewswire - November 4,
2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the
“Company”) (TSXV:VPT) (OTC:VPTDF) is pleased to announce it has appointed Justin
Leushner as CEO of Ventripoint. Dr. George Adams has resigned as CEO
and has been elected as Chairman of the Board of Directors of
Ventripoint.
Oct 17, 2019 12:07 pm ET
IIROC Trading Resumption - VPT
VANCOUVER, Oct. 17, 2019 /CNW/ - Trading resumes in:
Oct 17, 2019 09:10 am ET
Ventripoint Diagnostics Announces U.S. FDA Clearance for VMS+ 3.0 Whole Heart Analysis System
Toronto, Ontario – TheNewswire - October 17,
2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the
“Company”),
(TSXV:VPT), (OTC:VPTDF) is pleased to announce that they have received
U.S. Food and Drug Administration (FDA) clearance for the VMS+ 3.0
whole heart analysis system.
Oct 17, 2019 08:09 am ET
IIROC Trading Halt - VPT
VANCOUVER, Oct. 17, 2019 /CNW/ - The following issues have been halted by IIROC:
Oct 16, 2019 05:10 am ET
St. Michael's Hospital to Receive VMS+ 3.0 Whole-Heart Analysis System
Toronto, Ontario – TheNewswire - October 16,
2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the
“Company”) (TSXV:VPT)
(OTC:VPTDF) is pleased to
announce that St. Michael’s Hospital in Toronto will be receiving
the VMS+ 3.0 complete heart analysis system for use in clinical
evaluations of cardiac patients.
Oct 03, 2019 05:10 am ET
Ventripoint Announces Closing of Non-Brokered Private Placement
Toronto, Ontario – TheNewswire - October 3,
2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Corporation”) (TSXV:VPT)
(OTC:VPTDF)
announces the closing of a non-brokered private
placement (the “Private
Placement”).
Sep 26, 2019 05:09 am ET
Ventripoint Announces Extension of Private Placement and Shares for Debt Transaction
Toronto, Ontario – TheNewswire - September 26, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”) (TSXV:VPT)
(OTCQB:VPTDF) announces that, further to its news
release of August 16, 2019, the TSX Venture Exchange (the
“Exchange”) has granted an extension with respect to the duration of
the Corporation’s previously-announced private placement (the
“Private
Placement”). The outside date upon which final
acceptance of the Private Placement may be granted by the Exchange has
been extended to October 23, 2019. The Private Placement is subject to
the receipt of all necessary ap
Sep 19, 2019 05:09 am ET
Ventripoint Diagnostics Announces Justin Leushner as New President and Management Restructuring
Toronto, Ontario – TheNewswire - September 19,
2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the
“Company”) (TSXV:VPT)
(OTCQB:VPTDF) is pleased to
announce that Justin Leushner has been appointed the President of
Ventripoint.
Aug 21, 2019 05:08 am ET
Children's Hospital in Western Canada to Become First to Use Ventripoint Heart Analysis System for 3D Echocardiograms
Toronto, Ontario – TheNewswire - August 21, 2019 –
Ventripoint Diagnostics Ltd. (“Ventripoint”
or the “Company”),
(TSXV:VPT), (OTCQB:VPTDF) is pleased to announce that a children’s
hospital in Western Canada will be the first hospital to use the VMS+
3.0 software-only solution for the clinical assessment of pediatric
cardiac patients using 3D ultrasound.
Aug 16, 2019 02:08 am ET
Ventripoint Announces $2,000,000 Non-Brokered Private Placement and Cross Trade
Toronto, Ontario – TheNewswire - August 16, 2019 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Corporation”) (TSXV:VPT)
(OTC:VPTDF)
announces that it intends to complete a
non-brokered private placement (the “Private Placement”)
of up to 13,333,333 units of the Corporation (“Units”) at CDN$0.15
per Unit for total gross proceeds of up to CDN$2,000,000 (the
“Offering”). Each Unit will be comprised of: (i) one common share of
the Corporation (“Common
Share”); and (ii) one common share purchase
warrant (“Warrant”) with each Warrant exercisable for
one Common Share at an exercise price of
Aug 06, 2019 05:08 am ET
Ventripoint Commends Mazankowski Alberta Heart Institute on their Feasibility Study Finding the VMS+ System Can Obviate the Need for Contrast Agents for LV Volumes and EF
Toronto, Ontario –
TheNewswire
- August 06,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”) (TSXV:VPT) (OTC:VPTDF) is pleased to announce that Dr. Windram and his
group of researchers at the Mazankowski Alberta Heart Institute in
Edmonton have completed a clinical study on the ability of the VMS+
whole-heart analysis system to analyze 2D echocardiograms of
left-ventricle (LV) volumes and ejection fractions (LVEF) without the
need for intravenous ultrasonographic enhancing agents. This
feasibility study concluded: “The use of the Ventripoint
knowledge-based-reconstruction
Jul 31, 2019 06:07 am ET
Ventripoint Manufacturing Facility Passed Inspection and First Two VMS+ 3.0 Heart Analysis Machines Shipping to Western Canada
Toronto, Ontario –
TheNewswire
- July 31,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”) (TSXV:VPT) (OTC:VPTDF) is pleased to announce that its manufacturing
facility for the VMS+ 3.0 whole heart analysis system received its
initial inspection and passed on July 25th, 2019. The first two devices
are being fabricated and are on schedule to ship this week to fulfill
purchase orders at a Heart Institute and a Children’s Hospital in
Western Canada (see Ventripoint News Releases from July 15th & 16th, 2019).
Jul 23, 2019 05:07 am ET
A Second Canadian Heart Institute to Receive Ventripoint VMS+ 3.0 Whole-Heart Analysis System
Toronto, Ontario – TheNewswire - July 23, 2019 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”) (TSXV:VPT)
(OTCQB:VPTDF) is pleased to
announce that a second Canadian Heart Institute has ordered a VMS+ 3.0
complete heart analysis system for the assessment of adult cardiac
patients.
Jul 16, 2019 05:07 am ET
A Canadian Heart Institute to Receive Ventripoint VMS+ 3.0 Whole-Heart Analysis System
Toronto, Ontario – TheNewswire - July 16, 2019 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”,
(TSXV:VPT) (OTCQB:VPTDF)
is pleased to announce that a Canadian Heart Institute has ordered a VMS+ 3.0
complete heart analysis system for the assessment of cardiac
patients.
Jul 15, 2019 05:07 am ET
Canadian Children's Hospital to Receive Ventripoint VMS+ 3.0 For Clinical Assessment of Pediatric Cardiac Patients
Toronto, Ontario – TheNewswire - July 15, 2019 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”) (TSXV:VPT) (OTCQB:VPTDF) is pleased to announce
that a leading Canadian Children’s Hospital will be the first
pediatric hospital to receive the VMS+ 3.0 complete heart analysis
system for the clinical assessment of pediatric cardiac patients.
Jul 02, 2019 05:07 am ET
Ventripoint Receives CE Mark for Clinical Use of VMS+ 3.0 Whole-Heart Analysis System
Toronto, Ontario, -
TheNewswire
- July 2,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have received
CE Mark for the VMS+ 3.0 system allowing it to be sold for clinical
use throughout the European Union and other CE Mark countries. The
VMS+ system can be used for all four chambers of the patient’s heart
to obtain volumetric measurements and is a
valuable tool for clinicians when diagnosing patients with cardiac
problems.
Jun 25, 2019 05:06 am ET
(AUDIO ENHANCED!) Ventripoint VMS+3.0 Whole-Heart Analysis System Receives License for Clinical Use from Health Canada
Toronto, Ontario –
TheNewswire
- June 25,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have received
a license from Health Canada to market the VMS+3.0 cardiac system for
all patients where the Left Ventricle (LV),
Right Ventricle (RV), Left Atrium (LA), and Right Atrium (RA) volumes
and ejection fractions are warranted or desired.
Jun 21, 2019 08:06 am ET
Ventripoint to Exhibit VMS+ Technology at the American Society of Echocardiography Annual Scientific Sessions
Toronto, Ontario /
TheNewswire
/ June 21, 2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they are showcasing
the VMS+ 3.0 cardiac system and VMS+ Software Solution at the American
Society of Echocardiography’s 30th Annual Scientific Sessions in
Portland, Oregon.
Jun 17, 2019 05:06 am ET
Ventripoint Completes Usability Study for VMS+ 3.0 with Positive Results
Toronto, Ontario
– TheNewswire - June 17, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”,
TSXV:VPT, OTCQB:VPTDF) is proud to announce that they have completed
a usability study for the VMS+ 3.0 system with very positive results.
Jun 10, 2019 05:06 am ET
Ventripoint to Manufacture VMS+ 3.0 In-House at Toronto Headquarters
Toronto, Ontario /
TheNewswire /
June 10,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they will be
setting up manufacturing operations at their Toronto headquarters for
the new generation of VMS+ system. Manufacturing of the current VMS+
system was out-sourced to a contract manufacturer.
Jun 05, 2019 05:06 am ET
May 31, 2019 05:05 am ET
Ventripoint Achieves Major Milestone by Passing External Safety Testing for Next-Generation VMS+ 3.0
Toronto, Ontario /
TheNewswire
/ May 31,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have achieved
a major milestone by successfully passing the EMC/Safety Testing for
the VMS+ 3.0, which is required for regulatory premarket approvals in
Canada, United States and Europe.
May 21, 2019 06:05 am ET
Ventripoint Featured in Canadian Business Quarterly for Paving a New Path in Cardiology Care with its AI-Powered Technology
Toronto, Ontario /
TheNewswire
/ May 21,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have been
featured in the Canadian Business Quarterly publication for their
revolutionary VMS+ device that makes diagnosing and monitoring heart
diseases faster, less expensive and with equivalent accuracy to
MRI.
May 15, 2019 05:05 am ET
Ventripoint Signs an Authorized Sales Agent Agreement with Irudigi
Toronto, Ontario /
TheNewswire /
May 15,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they have signed an
Authorized Sales Agent Agreement with Irudigi out of France.
Apr 01, 2019 05:04 am ET
Ventripoint to Exhibit VMS+ 3.0 at the Canadian Society of Echocardiography 21st Annual Symposium
Toronto, Ontario /
TheNewswire
/ April 1,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that they are a proud
sponsor of the 21st Annual Canadian Society of Echocardiography Annual
Symposium and will be exhibiting the VMS+ 3.0 system.
Mar 25, 2019 05:03 am ET
Canada's Largest Heart Health Centre Orders VMS+ Complete Heart Analysis System
Toronto, Ontario, March 25,
2019 / TheNewswire
/ Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is
pleased to announce that the University of Ottawa Heart Institute has
ordered the VMS+ complete heart analysis system for the clinical
assessment of cardiac patients.
Mar 19, 2019 06:03 am ET
Ventripoint Provides Live Demonstrations of the VMS+3.0 System at American College of Cardiology 68th Annual Conference
Toronto, Ontario /
TheNewswire
/ March 19,
2019 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it successfully
showcased the next-generation VMS+3.0 system at the
American College of Cardiology’s 68th Annual Scientific Session
& Expo.
Mar 14, 2019 05:03 am ET
Ventripoint Announces TSXV Approval of Extension of Warrants and Clarifies Warrants Subject to Extension
NOT FOR DISTRIBUTION TO UNITED STATES
NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Mar 06, 2019 10:03 am ET
Mar 06, 2019 05:03 am ET
Ventripoint Announces Extension of Warrants
Toronto, Ontario /
TheNewswire
/ March 6, 2019 -
Ventripoint Diagnostics Ltd.
(“Ventripoint” or the
“Corporation”), (TSXV:VPT,
OTCQB:VPTDF) announces that it has applied to the TSX Venture Exchange
(the “TSXV”) to extend the expiry
dates of common share purchase warrants issued by the Corporation (the
“Warrants”) in connection with a
private placement on March 23, 2017 and a shares-for-debt transaction
on March 21, 2017 (collectively, the “Originating
Transactions”). The amendments to
the expiry dates of the Warrants are set out in the table below. The
Warrants to be amended do not include an
Mar 05, 2019 05:03 am ET
Mar 04, 2019 03:29 pm ET
IIROC Trading Resumption - VPT
VANCOUVER, March 4, 2019 /CNW/ - Trading resumes in:
Mar 04, 2019 09:19 am ET
IIROC Trading Halt - VPT
VANCOUVER, March 4, 2019 /CNW/ - The following issues have been halted by IIROC:
Mar 04, 2019 02:03 am ET
Feb 27, 2019 05:02 am ET
Ventripoint to Exhibit the VMS+ 3.0 System at American College of Cardiology Annual Conference and Grant of Options
Toronto, Ontario /
TheNewswire
/ February
27, 2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to
announce that it will be exhibiting at the American College of
Cardiology’s 68th Annual Scientific Session & Expo to showcase
its
next-generation VMS+ 3.0 system (http://2019.acccongress.com).
Feb 05, 2019 05:02 am ET
Ventripoint Diagnostics Reports Progress of the Next-Generation VMS+ 3.0 System and Remote Workstation
Toronto, ON / TheNewswire / February 5, 2019 – Ventripoint
Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT,
OTCQB:VPTDF) is pleased to announce the development stage of their
next-generation VMS+ 3.0 product is nearing completion. Usability
studies are being initiated at two leading Canadian hospitals to
establish effectiveness, efficiency,
and ease of use of the VMS+ 3.0. The
Company will be
submitting for regulatory market approvals in North America and Europe
as soon as these studies are completed.
Jan 28, 2019 05:01 am ET
Ventripoint Announces Closing of Non-Brokered Debenture Unit Private Placement
NOT FOR DISTRIBUTION TO
UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED
STATES
Jan 22, 2019 05:01 am ET
Ventripoint Awarded MDSAP Certification, the Highest Quality Standards in the Medical Device Industry
Toronto, ON / TheNewswire / January 22, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it
has successfully received the Medical Device Single Audit Program
(MDSAP) certification, following an audit of its quality management
system by our Notified Body/Registrar, an authorized third party
auditing organization.
Jan 21, 2019 09:01 am ET
Ventripoint Announces Increase in Non-Brokered Debenture Unit Private Placement
Toronto, Ontario / TheNewswire / January 21, 2019 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”,
TSXV:VPT) announces that as a result of positive investor response to its previously
announced non-brokered unit private placement (the "Offering"), as
disclosed in a news release dated January 9, 2019, the Corporation has
increased the size of the Offering from $1,000,000 to $1,500,000.
The Corporation has closed the order book on
the Offering and intends to complete the Offering of debenture units of the
Corporation at CDN$1,000 per Unit ("Unit") by
January 25, 2019.
Jan 09, 2019 05:01 am ET
Ventripoint Announces $1,000,000 Non-Brokered Debenture Unit Private Placement
Toronto, Ontario / TheNewswire / January 9, 2019 –
Ventripoint Diagnostics Ltd. (“Ventripoint” or the
“Corporation”, TSXV:VPT) announces that it
intends to complete a non-brokered private placement of up to
CDN$1,000,000 (the “Offering”) of debenture units of the
Corporation at CDN$1,000 per Unit (“Unit”). Each Unit
will be comprised of: (i) CDN$1,000 principal amount of convertible
unsecured debentures (“Debentures”), which shall mature three years
from the date of issuance; and (ii) 6,000 common share purchase
warrants (“Warrants”) with each Warrant exercisable for
one common share of the C
Jan 07, 2019 05:01 am ET
St. Antonius Hospital in Nieuwegein Utrecht, The Netherlands Has Studied 500 Sarcoidosis Patients Using the Ventripoint Heart-Analysis System
Toronto / TheNewswire / January 7, 2019 – Ventripoint
Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT,
OTCQB:VPTDF) is pleased to announce that Dr. M.C. Post, MD, PhD
Cardiologist and Dr. Marloes Huitema, MD, PhD
candidate Cardiology at St. Antonius Hospital in
Nieuwegein/Utrecht, the Netherlands, are using
the VMS System to study patients with sarcoidosis, an inflammatory disease that affects multiple organs in the
body, including the heart.
Dec 14, 2018 05:12 am ET
Ventripoint Performs Live Demonstrations of the Next-Generation VMS+ System at EuroEcho 2018
Toronto, Ontario /
TheNewswire /
December 14,
2018 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to
announce that it showcased the VMS+ 3.0 System at EuroEcho
2018 in Milan, Italy, one of the world’s largest cardiovascular imaging congress’ with 4,200
attendees.
Dec 13, 2018 02:12 am ET
Nov 29, 2018 05:11 am ET
Ventripoint to Exhibit the Next-Generation VMS+ System at EuroEcho in Milan, Italy
Toronto, Ontario /TheNewswire/ November 29, 2018 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to
announce that it will be exhibiting at EuroEcho 2018, the annual
congress of the European Association of Cardiovascular Imaging to
showcase the next-generation VMS+ System.
Nov 28, 2018 02:11 am ET
Ventripoint Diagnostics Announces Extension of Warrants
Toronto, Ontario /
TheNewswire
/ November 28,
2018 - Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Corporation”) (TSXV:VPT) announces that
it has applied to the TSX Venture Exchange (the “TSXV”) to amend
the expiry date of common share purchase warrants issued by the
Corporation in connection with a private placement of the Corporation
(the “Originating Private Placement”) on December 16, 2016 (the
“Warrants”). The amendment to the expiry date of the Warrants is
set out in the table below. The Warrants to be amended do not include
any warrants issued to finders or agents in connection w
Nov 20, 2018 05:11 am ET
Nov 19, 2018 06:11 am ET
Ventripoint's Product Offering is Now Extended to Include VMS+ Software for the Analysis of 3D Echo Studies
Toronto, Ontario /
TheNewswire
/ November 19,
2018 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the VMS+ Software
approved for all 4 chambers of the heart can be used for the analysis
of 3D echo images generated by any commercially available 3D
echocardiography system.
Nov 14, 2018 05:11 am ET
Ventripoint Has Been Approved for Government Support to Aid in the Extension of VMS Technology to Provide 4D Data
Toronto, Ontario / TheNewswire / November 14, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased
to announce that it has entered into a Contribution Agreement with the
Government of Canada. The National Research Council of Canada
Industrial Research Assistance Program (NRC IRAP) will provide both
advisory support and conditional funding to share the costs of a
project designed to accelerate the further
development of the Ventripoint VMS+ system’s next-generation
products.
Nov 12, 2018 05:11 am ET
St. Michael's Hospital, a Leading Cardiac Centre in Canada, Orders the Ventripoint Artificial Intelligence VMS+ Complete Heart Analysis System
Toronto, Ontario / TheNewswire / November 12, 2018 –
Ventripoint Diagnostics Ltd. (“Ventripoint”
or the “Company”, TSXV:VPT) is pleased to announce that St.
Michael’s Hospital in Toronto, Canada, has ordered the AI based
VMS+ complete heart analysis system for use in clinical evaluations of
cardiac patients.
Nov 05, 2018 06:11 am ET
The University of Chicago Medical Center Cardiac Department Evaluates the VMS+ Complete Heart Analysis System
Toronto, Ontario /
TheNewswire
/ November 5,
2018 – Ventripoint Diagnostics
Ltd. (“Ventripoint” or the
“Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that the University of
Chicago Medical Center in Chicago, Illinois will be receiving the VMS+
complete heart analysis system.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.